The Many Faces of Psoriasis | Part 1
			
		
			163211632116321 Psoriasis affects 2% of the world’s population and occurs in a bimodal distribution, peaking in early and late adulthood. Chronic plaque psoriasis is the most common variant and presents as well demarcated erythematous plaques with prominent white scale on the scalp and extremities.
The erythema of psoriasis varies across the spectrum of skin tones, ranging from a salmon and deep reddish  …
Psoriasis affects 2% of the world’s population and occurs in a bimodal distribution, peaking in early and late adulthood. Chronic plaque psoriasis is the most common variant and presents as well demarcated erythematous plaques with prominent white scale on the scalp and extremities.
The erythema of psoriasis varies across the spectrum of skin tones, ranging from a salmon and deep reddish  … 			
			
		 Psoriasis affects 2% of the world’s population and occurs in a bimodal distribution, peaking in early and late adulthood. Chronic plaque psoriasis is the most common variant and presents as well demarcated erythematous plaques with prominent white scale on the scalp and extremities.
The erythema of psoriasis varies across the spectrum of skin tones, ranging from a salmon and deep reddish  …
Psoriasis affects 2% of the world’s population and occurs in a bimodal distribution, peaking in early and late adulthood. Chronic plaque psoriasis is the most common variant and presents as well demarcated erythematous plaques with prominent white scale on the scalp and extremities.
The erythema of psoriasis varies across the spectrum of skin tones, ranging from a salmon and deep reddish  … 			 
	 








 INTRODUCTION
Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr …
INTRODUCTION
Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr … 